Immediate Impact
23 from Science/Nature 73 standout
Citing Papers
Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
2025 Standout
Works of Siminder Atwal being referenced
Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).
2021
Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma
2021
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Siminder Atwal | 195 | 601 | 218 | 378 | 244 | 15 | 890 | |
| Michael Andreeff | 90 | 331 | 257 | 366 | 159 | 18 | 996 | |
| Ladan Fazlollahi | 366 | 313 | 86 | 368 | 260 | 21 | 1.1k | |
| I Espinosa | 57 | 306 | 245 | 246 | 213 | 11 | 787 | |
| Laura Casorzo | 64 | 649 | 142 | 253 | 314 | 29 | 1.1k | |
| A. Rost | 267 | 854 | 373 | 235 | 357 | 12 | 1.1k | |
| Young-Hyeh Ko | 194 | 413 | 475 | 105 | 85 | 23 | 942 | |
| Anna-Maria Larsson | 32 | 472 | 61 | 339 | 129 | 26 | 834 | |
| Ruth Seggewiss‐Bernhardt | 149 | 403 | 75 | 113 | 230 | 20 | 869 | |
| Kabir A. Khan | 29 | 475 | 110 | 210 | 191 | 19 | 1.1k | |
| Stefanie Srock | 240 | 780 | 498 | 153 | 299 | 21 | 1.1k |
All Works
Loading papers...